Skip To Main Content
Marc Bardou on Muck Rack

Marc Bardou

As seen in: Color Research & Application, Nature, Le Figaro Santé, BMJ Open, Gut Journal, Libération, Taylor & Francis Online, Medscape, The New England Journal of Medicine, Annals of Internal Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marc

Contact Marc, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review

|
By Celine Jost, Alessandro Mussa, Jean-Emmanuel Kurtz, Ann Nordgren, Silvia Kalantari, Diana Carli, Andrea Gazzin, Claudio Isella, Enzo Medico, Thirona Naicker, Antoinette V. Chateau, Jean-Baptiste Demoulin, Nikolas Herold, Tara L. Wenger, Helena Iznardo, Eulalia Baselga, Jose Mascaro, Cecilie Bredrup, Titas Gladkauskas, Cecilie F. Rustad, Dinel Pond, Élise Schaefer, Maxime Luu, Marc Bardou, Laurence Faivre, Ashmika Gokhul, Anna Cassisa, Daniela Cantarella, Yordi-Michaël Bouhatous, Liubinka Mirakovska, Agnès Maurer, Théo Gaumet, Olav Aga Kildal, Ingrid Voktor Svinvik
| Nature Verified
Abstract Heterozygous activating variants in platelet-derived growth factor receptor beta (PDGFRβ) are associated with ultra-rare and clinically heterogeneous conditions, including KOGS (Kosaki Overgrowth Syndrome), PS (Penttinen Syndrome) and related conditons. Tyrosine kinase inhibitors (TKIs), which are widely used in hematological and oncological diseases, are now being explored as potential treatments for these conditions.
Open in Who Shared Issue with article?

Risk of cervical cancer and high-grade lesions in vulnerable women a systematic review and meta-analysis - Nature Communications

|
By Amir Hassine, Anna Tisler, Myriam Martel, Marc Bardou
| Nature Verified
Abstract Cervical cancer is largely preventable, yet causes around 300,000 deaths annually, disproportionately affecting vulnerable women. In here, we aim to estimate the risk of high-grade cervical lesions and cervical cancer among vulnerable populations in high- and upper-middle-income countries. We conduct a systematic review and meta-analysis of studies published up to February 2024 (from 2004 for HIV) across four databases. Risk of bias is assessed using the Newcastle–Ottawa Scale.
Open in Who Shared Issue with article?

la santé des femmes, un enjeu démocratique menacé

|
By Marc Bardou
| Le Figaro Santé
TRIBUNE - Le cancer du col de l'utérus illustre les inégalités en santé qui menacent les femmes en Europe. De véritables progrès sont possibles, mais ils restent fragiles. Le Pr Marc Bardou est chercheur Inserm au centre d'investigations cliniques du CHU Dijon‐Bourgogne, coordonnateur des projets européens sur la prévention du cancer du col de l'utérus, CBIG-SCREEN (https://cbig-screen.eu) et HPV-FASTER-implement (https://www.hpv-faster-implement.eu).
Open in Who Shared Issue with article?
See all 24 articles